Oxidative deamination of noradrenaline in human blood vessels

  • W. Osswald
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)


Human vascular tissue (saphenous vein and uterine artery) was incubated with tritiated noradrenaline. In both vessels, oxidative deamination predominated over O-methylation. Deamination was due to the action of MAO type A and B, as well as of a semicarbazide-sensitive oxidase. Whereas DOPEG was a good index of intraneuronal deamination, NMN, DOMA and OMDA appeared to be entirely extraneuronal in origin. Extraneuronal deamination plays an important role in human vascular tissue and may contribute to the inactivation of circulating catecholamines.


Monoamine Oxidase Saphenous Vein Uterine Artery Amine Oxidase Oxidative Deamination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bevan JA, Bevan RD, Duckies SP (1980) Adrenergic regulation of vascular smooth muscle. In: Bohr DF, Somlyo AP, Sparks Jr HV (eds) Vascular smooth muscle. Am Physiol Soc, Bethesda (Handbook of physiology, vol 2, section 2, pp 515–566).Google Scholar
  2. Bönisch H, Uhlig W, Trendelenburg U (1974) Analysis of the compartments involved in the extraneuronal storage and metabolism of isoprenaline in the perfused heart. Naunyn Schmiedebergs Arch Pharmacol 283:233–244.Google Scholar
  3. Branco D, Caramona MM, Araujo D, Osswald W (1990) The role of monoamine oxidase in the metabolism of exogenous noradrenaline by the human saphenous vein. (Submitted for publication).Google Scholar
  4. Branco D, Osswald W (1988) The influence of Ruscus extract on the uptake and metabolism of noradrenaline in the normal and varicose human saphenous vein. Phlebology 3 [Suppl] 1:33–39.Google Scholar
  5. Caramona MM, Osswald W (1985) Effects of clorgyline and (−) deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 328:396–400.PubMedCrossRefGoogle Scholar
  6. Clarke DE, Lyles GA, Callingham BA (1982) A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase. Inhibition by amphetamine, mexiletine and other drugs. Biochem Pharmacol 31:27–35.Google Scholar
  7. Coquil JF, Goridis C, Mark G, Neff NH (1973) Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br J Pharmacol 48:590–599.PubMedGoogle Scholar
  8. Docherty JR (1987) The use of the human saphenous vein in pharmacology. Trends Pharmacol Sci 8:358–361.CrossRefGoogle Scholar
  9. Fowler CJ, Callingham BA, Manie TJ, Tipton KF (1978) Monoamine oxidase A and B: a useful concept?. Biochem Pharmacol 27:97–101.CrossRefGoogle Scholar
  10. Graefe KH, Bönisch H (1988) The transport of amines across the axonal membranes of noradrenergic and dopaminergic neurons. In: Trendelenburg U, Weiner N (eds) Catecholamines I. Springer, Berlin Heidelberg New York Tokyo, pp 193–245.Google Scholar
  11. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297.PubMedCrossRefGoogle Scholar
  12. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sander M (eds) Monoamine oxidase — new vistas. Raven Press, New York (Adv biochem psychopharmacol, pp 393–408).Google Scholar
  13. Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37:333–364.PubMedGoogle Scholar
  14. Lyles GA (1984) The interaction of semicarbazide-sensitive amine oxidase with MAO inhibitors. In: Tipton KF, Dostert D, Strolin Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 547–556.Google Scholar
  15. Majewski H, Hedler L, Steppeler A, Starke K (1982) Metabolism of endogenous and exogenous noradrenaline in the rabbit perfused heart. Naunyn Schmiedebergs Arch Pharmacol 319:125–129.PubMedCrossRefGoogle Scholar
  16. Osswald W, Branco D (1973) The effects of drugs and denervation on removal and accumulation of noradrenaline in the perfused hind-limb of the dog. Naunyn Schmiedebergs Arch Pharmacol 277:175–190.PubMedCrossRefGoogle Scholar
  17. Osswald W, Guimarães S (1983) Adrenergic mechanisms in blood vessels: morphological and pharmacological aspects. Rev Physiol Biochem Pharmacol 96:53–122.PubMedCrossRefGoogle Scholar
  18. Osswald W (1986) Inactivation of catecholamines in the blood vessel wall. In: Magro A, Osswald W, Reis D, Vanhoutte PM (eds) Central and peripheral mechanisms of cardiovascular regulation. Plenum Press, New York London, pp 1–31.Google Scholar
  19. Osswald W (1988) Disposition of catecholamines in the blood vessel wall. In: Bevan JA, Majewski H, Maxwell RA, Story DF (eds) Vascular neuroeffector mechanisms. IRL Press, Oxford, pp 321–329.Google Scholar
  20. Trendelenburg U (1980) A kinetic analysis of the extraneuronal uptake and metabolism of catecholamines. Rev Physiol Biochem Pharmacol 87:33–115.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • W. Osswald
    • 1
  1. 1.Laboratório de FarmacologiaFaculdade de MedicinaPortoPortugal

Personalised recommendations